Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, 2-Part, Open-label, Single-Dose, Parallel Group Study to Determine the Effect of Hepatic Impairment on the Safety, Tolerability, and Pharmacokinetics of ACH-0144471 in Adult Subjects

Trial Profile

A Phase 1, 2-Part, Open-label, Single-Dose, Parallel Group Study to Determine the Effect of Hepatic Impairment on the Safety, Tolerability, and Pharmacokinetics of ACH-0144471 in Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jan 2019

At a glance

  • Drugs ACH 4471 (Primary)
  • Indications Glomerulonephritis; Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Focus Pharmacokinetics
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 08 Jan 2019 Status changed from recruiting to completed.
    • 19 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top